Skip to main content
SpringerLink
Log in

Dacomitinib not cost effective for first-line therapy of advanced NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhang L, et al. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. Cancer Management and Research 13: 4263-4270, 28 May 2021. Available from: URL: https://doi.org/10.2147/CMAR.S293983

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dacomitinib not cost effective for first-line therapy of advanced NSCLC. PharmacoEcon Outcomes News 880, 8 (2021). https://doi.org/10.1007/s40274-021-7766-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7766-0

Search

Navigation